Four recommendations can move Indonesia toward achieving HIV epidemic control

By on .

The following is a guest post by Cathy Cantelmo, Rebecca Ross, Shree Prabhakaran and Arin Dutta Indonesia has not yet achieved UNAIDS 90-90-90 HIV treatment targets or epidemic control. Of the people living with HIV as of June 2020, only 63 percent knew their status, just a quarter were on antiretroviral therapy, and a mere […]

Representing a quarter of Denver’s population, Latinx residents bear the brunt of COVID-19 with more than half of all sicknesses, deaths

By on .

From March 6, when the first diagnosis of COVID-19 in Denver, Colorado was confirmed, to October 6, more than 10,000 adults living outside of detention, long-term care, or shelter settings were diagnosed with the disease. More than a thousand were hospitalized, and 165 people died as a result of the disease. Of all of the […]

World AIDS Day reminds us that the toll of the world’s longest pandemic continues throughout the year

By on .

Inboxes fill fast on commemorative days like these with reminders of a challenge that has tragic impacts throughout the year. Often these days can seem to serve as a pass for remembering, discussing, pressing for solutions to the challenge on all the other days. In a year when a new pandemic has both dominated our […]

A plan maintains continuity of HIV care in a Nigerian state during COVID-19 lockdown

By on .

The following is a guest post by Tyra Fom of Data.FI The COVID-19 pandemic poses a double threat for people living with HIV, who must find ways during lockdown to access their antiretroviral therapy from overwhelmed health facilities. In addition, people who have the virus but are not yet diagnosed face challenges getting tested and […]

Five questions on new data from China-WHO showing 124 confirmed coronavirus patients in December 2019

By on .

By Daniel R. Lucey M.D., MPH, FIDSA After China initially reported 41, then ~ 46, and then ~ 100 laboratory-confirmed cases in December 2019, a total of 124 confirmed cases in December was reported by China July 31 but for some reason only posted on the WHO website Nov. 5. First posted on the WHO […]

COVID-19: Data on health care worker infections, deaths from 37 countries highlight PPE, training, protocol gaps

By on .

Authors call on WHO to track, post nation-by-nation numbers showing impacts on health personnel A paper published today in the International Journal of Infectious diseases provides information for the first time on the toll of COVID-19 on health care workforces across 37 countries. The data, from the Americas, Asia, Europe, Africa and Middle Eastern nations […]

COVID-19: WHO-China team “Terms of Reference” reveal new data on seafood market

By on .

By Daniel R. Lucey M.D., MPH, FIDSA On Nov. 5, the World Health Organization posted on its website an important nine-page document titled: “WHO-Convened Global Study of the Origins of SARS-CoV2: Terms of Reference for the China Part.” This document is important for many reasons.  First, it is dated 31 July 2020 (upper left under […]

Pfizer/BioNTech COVID-19 vaccine efficacy: Six key questions

By on .

By Daniel R. Lucey M.D., MPH, FIDSA The Pfizer/BioNTech announcement today on findings from their first interim analysis of its Phase 3 COVID-19 vaccine candidate study showing 90% efficacy among 94 cases included the following excerpts, with key data pending: “Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned […]

COVID-19: With high tide waves across America, a request to the National Academy of Medicine on masks

By on .

By Daniel R. Lucey M.D., MPH, FIDSA Today the Washington Post reported the United States had recorded the highest number of new cases (104,004) in one day, the highest number of hospitalizations in 18 states and 1,114 more deaths. In my opinion, the National Academy of Medicine should convene this month to provide a public […]

COVID-19: When will FDA convene an independent advisory committee for monoclonal antibody EUAs?  

By on .

By Daniel R. Lucey M.D., MPH, FIDSA Rapidly evolving events regarding studies of monoclonal antibodies reemphasize the call first made here Oct. 19  that the U.S. Food and Drug Administration convene an outside expert advisory committee ASAP to advise on requests for Emergency Use Authorization for monoclonal antibodies against SARS-CoV-2. On Oct. 7 Lilly announced […]